Skip to content
‹ Back to IndustriesSciences

On the way to Space, Billionaires Look for Business Partners

The world is in a new space race. This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk. This billionaire space race, as it is being called, has resulted in the creation of just as many companies. Musk’s SpaceX and Branson’s…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Troy Camplin · · BezosBlue OriginElon MuskScience
Share
On the way to Space, Billionaires Look for Business Partners

Key takeaways

01

The world is in a new space race.

02

This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk.

03

This billionaire space race, as it is being called, has resulted in the creation of just as many companies.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The world is in a new space race. This time, though, it is not the United States versus the Soviet Union; instead, it is Jeff Bezos versus Richard Branson versus Elon Musk.

This billionaire space race, as it is being called, has resulted in the creation of just as many companies. Musk’s SpaceX and Branson’s Virgin Galactic may grab the headlines, but there is also Bezos’ Blue Origin, and Milner’s Breakthrough Starshot. The late Paul Allen also started Stratolaunch.

Each is aimed at somewhat different aspects of space travel, but one thing they all have in common is a competitive—and cooperative—spirit that is driving a great deal of technical innovation.

Companies like SpaceX are finding that it is important to partner with other companies to be successful. NASA and companies like Iridium have partnered with SpaceX to put satellites in orbit. Land Rover and Abu Dhabi, meanwhile, have chosen to partner with Virgin Galactic, who is also partnering with Boom Technology to create a supersonic passenger transporter. While SpaceX has NASA, Blue Origin is partnered with the Air Force for launch services.

There is a healthy need for space services and for creating strong partnerships to develop the technology needed, but what new technologies are on the horizon?

SpaceX has been having more and more success with its rockets, and it famously was able to land a rocket on a sea platform. Elon Musk has also been talking about going to Mars, and that will take some serious improvements in technology. In fact, SpaceX is currently working with NASA on developing a Mars-landing mission.

Blue Origin has developed New Shepard, a suborbital, reusable launch vehicle, and New Glenn, an orbital, reusable launch vehicle.

Virgin Galactic has long talked about the creation of a space plane that will make space tourism feasible. On Dec. 13, Virgin Galactic came a lot closer to realizing that dream when it was able to fly its VSS Unity to the edge of space.

With plans for the moon and Mars, including the possibility of 3D printing structures for people to potentially visit or inhabit, the sky is absolutely not the limit for these visionaries. While the space race between the USA and the USSR got man into space in the first place, and even placed a few men on the moon, the billionaires’ space race looks to take space technology, research, and exploration to new heights. Only time will tell what benefits all of this will bring.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

TC
Troy Camplin
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

TC
Troy Camplin

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512